Redd&Whyte Appoints HighRes Biosolutions as New US Distributor
News Feb 28, 2013
Redd&Whyte, an expert supplier of liquid handling automation for drug discovery and life science research applications, today announced it has appointed HighRes Biosolutions, a leading developer of flexible laboratory automation systems, as US distributor for its Preddator low-volume microplate dispensers. The appointment will provide US researchers with rapid access to, and support of, unique technology for achieving consistent results and reducing assay costs, by dispensing low-volumes of difficult reagents into microplates.
Under the terms of the agreement, HighRes Biosolutions will market Redd&Whyte’s Preddator range in North America. The versatile Preddator, which can dispense viscous liquids including gels, cell suspensions and DMSO in any microplate format from 96-3456 wells, will be integrated into HighRes’ patented MicroDock technology. This will allow scientists to easily add and remove the Preddator from HighRes’ automated assay preparation and screening systems.
Redd&Whyte chose HighRes to market its equipment in North America because the firm is respected for its modular design of versatile laboratory automation and specialist knowledge of integrating state-of-the-art liquid handlers into their systems. HighRes also has a large network of life science specialists across the USA, who will provide further information on integrated solutions that include the Preddator system.
Roger Poole, Managing Director of Redd&Whyte commented: "Recently, we have had great success in the North American market with our Preddator system and are delighted to have HighRes Biosolutions as our new distribution partner to support this growth.”
Poole added: “HighRes is a first-rate company, with an excellent reputation for its versatile approach to integrating only the best low-volume liquid handlers into their systems. Our unique, flexible low-volume microplate dispensing technology will perfectly complement the products HighRes provides so we’re excited to have them offering Preddator as part of their portfolio.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE